Diamond Light Source

ORN's first external Virtual Environment

Tim Dudgeon (IM)

on behalf of

Frank von Delft, Rachael Skyner











Fragment screening at Diamond






Why an OpenRiskNet Virtual Environment?

- Existing solution no need to develop
- Built on robust platform (OpenShift/Kubernetes)
- Support/expertise available locally (IM)
- Availability of ORN applications (Squonk, ADMET predictions)
- Allows to deploy Diamond specific apps
- CI/CD process







The Diamond VE

- Running on 'bare metal' OpenStack cluster (*Ironic*) on Verne Global cloud in Iceland
 - 1 Bastion
 - 1 Master node 4 cores, 32GB RAM
 - 1 Infra node 20 cores, 128GB RAM
 - 1 Worker node- 20 cores, 128GB RAM
 - 1 HiMem node 20 cores, 512GB RAM (for Neo4j graph database)
 - 1 GPU node (little used so far)
- OpenShift cluster deployed using the standard ORN deployment tools
 - Including some of the ORN applications
- This cluster interacts with computing facilities and data at Diamond and STFC (both on Harwell Campus)

Core app stack - Fragalysis: https://fragalysis.diamond.ac.uk



Jenkins



Ongoing work

- Integration with HPC (docking, MD techniques)
 - Workflow tool integration (Squonk, Galaxy)
 - PySquonk
- Application enhancements
- Improve deployment (for Pharma)
 - Simplify and streamline
 - Better customisation
- Work being planned to at least end 2020

PySquonk

- Python modules that:
 - Allow access computational services from Squonk
 - Docking
 - Property prediction/filtering
 - Other cheminformatics and comp chem tools
 - In future ADMET tools and predictions
 - Will be integrated into Fragalysis
 - Exemplified using Jupyter notebooks
- Work being done as part of the ORN implementation challenge
 - Expected to be complete by end November

Summary

- The ORN VE was a natural choice for Diamond
- OpenShift/Kubernetes provides a powerful and flexible platform for deploying scientific applications
- CI/CD processes have been critical
- Establishes a route for uptake of ORN VE by pharma
- Work continues!